fundvisualizer.com

Loncar China BioPharma ETFCHNA

Performance (before sales charge)

As of 08/31/2023

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 08/31/2023
Stock
7.10%
Non-U.S. Stock
92.13%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.77%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 08/31/2023

Basic materials

0.00%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

0.00%

Health care

99.23%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 08/31/2023

AIM Vaccine Co Ltd Class H
4.45%
Legend Biotech Corp ADR
3.07%
Wuxi AppTec Co Ltd
2.70%
Sinopharm Group Co Ltd
2.56%
BeiGene Ltd ADR
2.53%
Shanghai Haohai Biological Technology Co Ltd Shs -H- Unitary 144A/Reg S
2.47%
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
2.29%
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Class H
2.10%
Shanghai Pharmaceuticals Holding Co Ltd Class H
2.05%
WuXi Biologics (Cayman) Inc
2.03%
Fund assets

$4.16 Million

Share class

--

Morningstar category

China Region

Expense ratio

0.79%

Investment objective

Specialty - Health

Documents